Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Q4 Results
Tweet Send to a Friend
(Updated - February 19, 2026 10:25 AM EST)
Benchmark analyst Robert Wasserman raised the price target on Halozyme Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Benchmark analyst Robert Wasserman raised the price target on Halozyme Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
